Trump’s second inning is likely to spell uncertainty for pharma companies, says Nandini Piramal, referring to his plan to impose import tariffs to make American industry stronger.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.